[6]Tong JH, et al. MET Amplification and Exon 14 Splice Site Mutation Define Unique Molecular Subgroups of Non-Small Cell Lung Carcinoma with Poor Prognosis. Clin Cancer Res. 2016;22(12):3048-56. [7]Mazieres J, et al. Immune...
尽管MET抑制剂相关外周水肿发生率很高,但通常为轻至中度,只有一小部分患者需要中断或停止MET抑制剂治疗。 — 参考文献 — 1.Nishio M, Kato T, Toyozawa R, Hida T. Management of Peripheral Edema in Patients with MET Exon 14-Mutated Non-small Cell Lung ...
[5] Puccini, A., Marín-Ramos, N.I., Bergamo, F. et al. Safety and Tolerability of c-MET Inhibitors in Cancer. Drug Saf 42, 211–233 (2019). [6] Wolf J, Edward B, Harry J.M et.al. Capmatinib in MET exon 14-mutated, advanced NSCLC: updated results from the GEOMETRY mono-1...
Response to MET inhibitors in patients with stage IV lung adenocarcinomas harboring MET mutations causing exon 14 skipping. Cancer Discov. 2015 Aug;5(8):842-9. doi: 10.1158/2159-8290.CD-14-1467. Epub 2015 May 13. Erratum in: Cancer Discov. 2016 Mar;6(3):330. PMID: 25971939;[4] Dril...
The promise of selective MET inhibitors in non-small cell lung cancer with MET exon 14 skipping. Cancer Treat Rev 2020; 87: 102022. 7. Vuong HG, Ho ATN, Altibi AMA, Nakazawa T, Katoh R, Kondo T. Clinicopathological implications of MET exon 14 mutations in non-small cell lung cancer...
该病例为肺肉瘤样癌(PSC),初诊为Ⅳ期(cT4N2M1a),基因检测为MET14号外显子跳跃突变,一线使用克唑替尼进行治疗,4个月后评价为疾病进展(PD)。二线治疗时,患者被检测为MET14号外显子跳跃突变并伴有MET扩增,且PD-L1高表达,由于当时国内没有相应的靶向药物上市,遂使用免疫治疗PD-1抑制剂进行治疗,治疗约22个月,...
[3] [ PMID: 25971938] Frampton, Garrett M et al. “Activation of MET via diverse exon 14 splicing alterations occurs in multiple tumor types and confers clinical sensitivity to MET inhibitors.” Cancer discovery vol. 5,8 (2015): 850-9. doi:10.1158/2159-8290.CD-15-0285. ...
1. Frampton, G.M., et al., Activation of MET via Diverse Exon 14 Splicing Alterations Occurs in Multiple Tumor Types and Confers Clinical Sensitivity to MET Inhibitors. Cancer Discovery, 2015. 5(8): p. 850-859.2. Siegel, R.L., K.D. Miller, and A. Jemal, Cancer statistics, 2018....
5. Underiner T L, Herbertz T, Miknyoczki S J.Discovery of small molecule c-Met inhibitors: Evolution and profiles ofclinical candidates. Anticancer Agents Med Chem. 2010, 10(1): 7-27. 6. Ou S-HI, Young L, Schrock AB, et al.Emergence of preexisting MET y1230cmutation as a resis...
精准定位才能精准打击,相信随着检测技术的发展,具有 MET 14 号外显子跳跃突变的患者将不再与靶向治疗「擦肩而过」。 参考文献 1. Paik PK, et al. Response to MET inhibitors in patients with stage IV lung adenocarcinomas harboring ME...